Ratings by Raymond James (Chris Raymond)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/9/2026 | Nuvalent | NUVL | Downgrade | Market Perform (Outperform) |
88.49 (123.96) |
40.08% | Details | |
| 6/4/2026 | Tyra Biosciences | TYRA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/27/2026 | Biohaven Pharma | BHVN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/12/2026 | Kalaris | KLRS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 5/12/2026 | Sionna Therapeutics | SION | Maintain | Strong Buy (N/A) |
|
Details | ||
| 4/29/2026 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/22/2026 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/8/2026 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2026 | Kalaris | KLRS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/27/2026 | Monopar Therapeutics | MNPR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/26/2026 | MeiraGTx Holdings plc | MGTX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/24/2026 | Aardvark Therapeutics Inc | AARD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/19/2026 | Taysha Gene Therapies | TSHA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/17/2026 | Kalaris | KLRS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/16/2026 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/9/2026 | Biohaven Pharma | BHVN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 3/9/2026 | Kalaris | KLRS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/3/2026 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/28/2026 | Tyra Biosciences | TYRA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/13/2026 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/13/2026 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/12/2026 | Aardvark Therapeutics Inc | AARD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/8/2026 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/7/2026 | Monopar Therapeutics | MNPR | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Taysha Gene Therapies | TSHA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/5/2026 | Sionna Therapeutics | SION | Maintain | Strong Buy (N/A) |
|
Details | ||
| 1/2/2026 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/30/2025 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/12/2025 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/11/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/8/2025 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 12/3/2025 | Aardvark Therapeutics Inc | AARD | New Coverage | Strong Buy (N/A) |
9.52 (5.86) |
-38.45% | Details | |
| 11/25/2025 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/20/2025 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/18/2025 | Kalaris | KLRS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/14/2025 | Monopar Therapeutics | MNPR | Downgrade | Outperform (Strong Buy) |
87.01 (111.12) |
27.71% | Details | |
| 11/12/2025 | Kalaris | KLRS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/11/2025 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/5/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/5/2025 | Sionna Therapeutics | SION | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/5/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/3/2025 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Strong Buy (N/A) |
|
Details | ||
| 10/21/2025 | Taysha Gene Therapies | TSHA | New Coverage | Strong Buy (N/A) |
4.72 (5.96) |
26.27% | Details | |
| 10/21/2025 | MeiraGTx Holdings plc | MGTX | New Coverage | Strong Buy (N/A) |
7.75 (12.44) |
60.52% | Details | |
| 10/6/2025 | Monopar Therapeutics | MNPR | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/26/2025 | Ardelyx, Inc | ARDX | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/22/2025 | Cogent | COGT | Maintain | Strong Buy (N/A) |
|
Details | ||
| 9/2/2025 | Vertex | VRTX | New Coverage | Market Perform (N/A) |
391.02 (485.65) |
24.2% | Details | |
| 9/2/2025 | Tyra Biosciences | TYRA | New Coverage | Strong Buy (N/A) |
12.67 (32.13) |
153.59% | Details | |
| 9/2/2025 | Sionna Therapeutics | SION | New Coverage | Strong Buy (N/A) |
24.62 (49.41) |
100.69% | Details | |
| 9/2/2025 | Nuvalent | NUVL | New Coverage | Outperform (N/A) |
76.58 (88.49) |
15.55% | Details | |
| 9/2/2025 | Monopar Therapeutics | MNPR | New Coverage | Strong Buy (N/A) |
34.15 (87.01) |
154.79% | Details | |
| 9/2/2025 | Kalaris | KLRS | New Coverage | Strong Buy (N/A) |
4.08 (4.38) |
7.35% | Details | |
| 9/2/2025 | Cogent | COGT | New Coverage | Strong Buy (N/A) |
12.08 (39.08) |
223.51% | Details | |
| 9/2/2025 | Ardelyx, Inc | ARDX | New Coverage | Strong Buy (N/A) |
6.36 (5.20) |
-18.24% | Details | |
| 9/2/2025 | Amgen | AMGN | New Coverage | Market Perform (N/A) |
287.71 (366.29) |
27.31% | Details | |
| 9/2/2025 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Outperform (N/A) |
58.27 (59.59) |
2.27% | Details | |
| 9/2/2025 | Biohaven Pharmaceutical Holding | BHVN | New Coverage | Strong Buy (N/A) |
15.39 (15.44) |
0.32% | Details | |
| 9/2/2025 | Regeneron Pharma | REGN | New Coverage | Outperform (Market Perform) |
580.70 (676.69) |
16.53% | Details |
